There was no significant difference in overall survival between treatment groups , with a median overall survival of 113 months ( 95 % CI 95-134 ) in the necitumumab plus pemetrexed and cisplatin group versus 115 months ( 101-131 ) in the pemetrexed and cisplatin group ( hazard ratio 101 [ 95 % CI 084-121 ] ; p = 096 ) .